{
  "nct_id": "NCT26842489",
  "indication": "Rheumatoid Arthritis",
  "phase": "Phase 1/2",
  "sample_size": 248,
  "duration_weeks": 56,
  "dropout_rate": 0.21,
  "primary_endpoints": [
    "ACR20 response"
  ],
  "secondary_endpoints": [
    "Joint damage progression",
    "DAS28 score reduction"
  ],
  "blinding": "open-label",
  "control_arm": "standard of care",
  "outcome_summary": "Study benefit-risk profile does not support further development.",
  "success": false,
  "failure_reason": "Dosing limitations due to side effects"
}